A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430

Phase 1 Completed 32 enrolled BioCryst Pharmaceuticals National Institute of Allergy and Infectious Diseases (NIAID) · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion

Timeline

Start: 2018-12-10
Primary completion: 2019-04-30
Completion: 2019-04-30

Publications

Mathis A, Collins D, Dobo S, Walling DM, Sheridan WP, Taylor R. Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2022 Apr;11(4):467-474. doi: 10.1002/cpdd.1037. Epub 2022 Feb 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Galidesivir	Small molecule	—	Intravenous

A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430

Summary

Timeline

Publications

Drugs

Indications